GSK Settles Zantac Lawsuits: A New Chapter for the Controversial Drug
The concerns surrounding Zantac also prompted UK health authorities to advise doctors in 2019 to cease prescribing specific formulations of the drug as a precautionary measure. Reports indicated that certain versions might contain impurities linked to cancer,
UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over ...
In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a ...
GlaxoSmithKline Pharma is shifting focus to specialty treatments and preventive healthcare, emphasizing adult vaccines and ...
U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...
In a report released today, Rajan Sharma from Goldman Sachs maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a ...
While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case ...
GlaxoSmithKline Pharma, celebrating 100 years in India, is shifting to a specialty-focused model by entering the oncology ...
GSK said a dose of its RSV vaccine protected against illness over three years, according to new data presented at the CHEST ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback